(Source: MARKET WIRE)
Vicor Technologies, Inc. (OTCBB: VCRT) today announced that it entered into an OEM product agreement with Nasiff Associates, Inc. to integrate its PD2i software into Nasiff's Cardio Card ECG. Vicor Technologies is a development-stage biotechnology company focused on the commercialization of non-invasive diagnostic products using its patented, proprietary PD2i algorithm and software to analyze heart rate variability and identify individuals at risk of sudden cardiac death, trauma victims requiring immediate life saving intervention, and diabetics at risk of developing diabetic autonomic neuropathy.
Under the agreement, entered into on May 12, 2009, Nasiff will manufacture the PD2i Cardiac Analyzer ECG for sale to physicians by Vicor and Nasiff under joint marketing rights. Both parties have agreed to develop and coordinate a joint marketing plan to promote this new product.
"We're very pleased to be working with Nasiff -- the developer of the world's first PC ECG -- to commercialize the PD2i Analyzer, the first of our PD2i applications to receive FDA 510(k) marketing clearance. A leading producer of medical diagnostic products linked to PCs, Nasiff will capture the precision of our PD2i algorithm in an easy-to-use diagnostic tool," stated Mr. Fater, Vicor's President and CEO. "It is expected that Vicor will receive revenue from both the sale of the equipment and from the analysis of the test results. Given the relatively low cost and ease of use of the PD2i Cardiac Analyzer ECG, we anticipate speedy adoption by a variety of physicians who value accurate measurement of heart rate variability as a diagnostic tool for a wide range of conditions," Mr. Fater concluded.
About Nasiff Associates, Inc.
Established in 1989 to develop the world's first PC ECG/PC EKG, Nasiff Associates, is a medical technology company committed to providing medical PC solutions to healthcare professionals by developing medical diagnostic and administrative products, which integrate into any personal computer.
About Vicor Technologies, Inc.
Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i) and software. The PD2i is a deterministic, non-linear analytic measure that accurately evaluates biological signals o predict with high sensitivity and high specificity future pathological events in target populations.
Vicor currently has three products employing the PD2i algorithm. The PD2i Analyzer, now in commercialization, measures heart rate variability. The PD2i VS (Vital Sign), in clinical trials under a collaborative effort with the U.S.
